• AnaptysBio Inc (NASDAQ: ANAB) has announced updated data from the GALLOP Phase 2 trial of imsidolimab in generalized pustular psoriasis (GPP).

• GPP is a rare and extreme form of psoriasis characterized by the presence of sterile pustules.

• The 16-week data were presented at the 2021 European Academy of Dermatology and Venereology (EADV) Congress.

• Data from 8 patients showed that 6/8 patients treated with imsidolimab monotherapy achieved the primary endpoint of response on the clinical global impression (CGI) scale at week 4 and week 16, without requiring rescue medication.

• Two of 8 patients were considered to have not met the primary endpoint because they dropped out of the trial before Day 29.

• Modified Japanese Dermatology Association severity index total score decreased on average by 29% at week 1, 54% at week 4, and 58% at week 16.

• Erythema with pustules decreased by 60% at week 1, 94% by week 4, and 98% by week 16.

• Imsidolimab was generally well-tolerated, and most treatment-emergent adverse events were mild to moderate in severity and resolved without sequelae.

• Phase 3 GEMINI-1 trial has been initiated after an end-of-Phase 2 meeting with the FDA.

• In addition to GPP, imsidolimab clinical development focuses on moderate-to-severe acne and moderate-to-severe hidradenitis suppurativa, with Phase 2 top-line data anticipated in these indications during 1H and 2H of 2022, respectively.

• Related: AnaptysBio's Imsidolimab Fails To Separate From Placebo In Skin Blistering Disorder Study.

• Price Action: ANAB stock traded lower by 0.18% at $27.54 on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• Teva Stops Production At US Plant After FDA Concerns: Report

• CTI BioPharma's COVID-19 Candidate Misses Primary Endpoint Mark In Phase 2 Trial

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.